

Date: 11/07/2017

FREEDOM OF INFORMATION REQUEST FOI/013509 – biologics and biosimilars

Could you please provide me with the numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs within the dermatology or gastroenterology departments.

Dermatology Gastroenterology

Abatacept (Orencia)  
Adalimumab (Humira)  
Apremilast (Otezla)  
Certolizumab Pegol (Cimzia)  
Etanercept (Enbrel)  
Etanercept biosimilar (Benepali)  
Fumaric Acid Esters N/A  
Golimumab (Simponi)  
Infliximab (Remicade)  
Infliximab biosimilar (Inflectra)  
Infliximab biosimilar (Remsima)  
Rituximab (MabThera)  
Secukinumab (Cosentyx)  
Ixekizumab (Taltz)  
Tocilizumab (RoActemra)  
Ustekinumab (Stelara)  
Vedolizumab (Entyvio)

All high cost drugs now require pre-approval before these can be prescribed / dispensed.

Most CCGs are using Blueteq <https://www.blueteq-secure.co.uk/trust/Default.aspx> : NHS High Cost / IFR database to ensure Acute providers undertake pre-approval verification of high cost drugs. This database is not locally configurable and as such The Trust is unable to extract reports by drug and indication. Individual CCGs may be able to do this.